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Abstract
 
NY-ESO-1 is a member of the cancer-testis family of tumor antigens that elicits strong humoral
 
and cellular immune responses in patients with NY-ESO-1–expressing cancers. Since CD4
 
1
 
 T
lymphocytes play a critical role in generating antigen-specific cytotoxic T lymphocyte and anti-
body responses, we searched for NY-ESO-1 epitopes presented by histocompatibility leukocyte
antigen (HLA) class II molecules. Autologous monocyte-derived dendritic cells of cancer patients
were incubated with recombinant NY-ESO-1 protein and used in enzyme-linked immunospot
(ELISPOT) assays to detect NY-ESO-1–specific CD4
 
1
 
 T lymphocyte responses. To identify
possible epitopes presented by distinct HLA class II alleles, overlapping 18-mer peptides derived
from NY-ESO-1 were synthetized and tested for recognition by CD4
 
1
 
 T lymphocytes in autol-
 
ogous settings. We identified three NY-ESO-1–derived peptides presented by DRB4
 
*
 
0101–
0103 and recognized by CD4
 
1
 
 T lymphocytes of two melanoma patients sharing these HLA class
II alleles. Specificity of recognition was confirmed by proliferation assays. The characterization of
HLA class II–restricted epitopes will be useful for the assessment of spontaneous and vaccine-
induced immune responses of cancer patients against defined tumor antigens. Further, the thera-
peutic efficacy of active immunization using antigenic HLA class I–restricted peptides may be im-
proved by adding HLA class II–presented epitopes.
Key words: HLA class II–restricted NY-ESO-1 epitopes • CD4
 
1
 
 T cell recognition
 
Introduction
 
Cancer-testis (CT)
 
1
 
 antigen NY-ESO-1, initially cloned by
the SEREX (serological analysis of recombinant tumor
cDNA expression libraries) approach from an esophageal
cancer (1), elicits humoral and cellular immune responses in
a high proportion of patients with NY-ESO-1–expressing
cancers (2, 3). This is in contrast to other defined tumor
differentiation antigens (TAs), which either induce CTL
responses but rarely antibody responses (e.g., melanocyte
differentiation antigens), or are of generally low im-
munogenicity, eliciting cellular or humoral immune re-
sponses in 
 
,
 
5% of patients with antigen-expressing cancers
(MAGE-1 and -3 antigens; reference 2, and Jäger, E., un-
published data).
 
The high frequency of detectable antibody and CTL
responses against NY-ESO-1 in patients with NY-ESO-
 
1
 
1
 
 tumors indicates the presence of spontaneous CD4
 
1
 
 T
cell responses, supporting the generation and maintenance
of both NY-ESO-1–specific antibody and CTLs. To fur-
ther analyze the role of CD4
 
1
 
 T cell responses in the spe-
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Abbreviations used in this paper: 
 
CT antigen, cancer-testis antigen;
ELISPOT, enzyme-linked immunospot; TA, tumor antigen.
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cific recognition of NY-ESO-1, we searched for NY-
ESO-1 epitopes presented by defined HLA class II alleles
and recognized by HLA class II–matched CD4
 
1
 
 T lym-
phocytes of cancer patients. Monocyte-derived autolo-
gous dendritic cells incubated with recombinant NY-
ESO-1 protein or lysates from an NY-ESO-1
 
1
 
 tumor cell
line and overlapping 18-mer NY-ESO-1 peptides were
used to detect peptide-specific CD4
 
1
 
 T cell responses in
enzyme-linked immunospot (ELISPOT) and proliferation
assays. We report here the identification of three new
NY-ESO-1 epitopes recognized by CD4
 
1
 
 T lymphocytes
of two melanoma patients in the context of HLA-
DRB4
 
*
 
0101–0103.
 
Materials and Methods
 
Patients.
 
Seven HLA-A2
 
1
 
 patients with NY-ESO-1–express-
ing metastatic melanoma or soft tissue sarcoma were assessed for
CD4
 
1
 
 T cell responses against recombinant NY-ESO-1 protein
and HLA-DRB4
 
*
 
0101–0103-binding NY-ESO-1 peptides. All
patients were positive for NY-ESO-1 serum antibodies in West-
ern blotting and ELISA as described (2). Patient characteristics are
presented in Table I. The expression of NY-ESO-1 in tumor tis-
sues was assessed by reverse transcriptase PCR as described (1).
 
Peptides.
 
To identify potential HLA class II–binding peptides,
28 peptides derived from NY-ESO-1 consisting of 18 amino ac-
ids with overlapping sequences were synthesized using an
Abimed 422 multiple peptide synthesizer. Peptides were isolated
and purified by repeated ether precipitations. The purity was de-
termined by analytical reverse phase HPLC and proved to be at
least 90%. Integrity of the peptides was determined by laser de-
sorption time-of-flight mass spectrometry on a Lasermat mass
spectrometer (Finnigan MAT).
 
Recombinant NY-ESO-1 and SSX Proteins.
 
NY-ESO-1 and SSX
proteins were expressed in 
 
Escherichia
 
 
 
coli
 
 as full-length proteins
with a six-histidine tag on the NH
 
2
 
 terminus (2). The proteins
were purified from washed and solubilized inclusion bodies by
nickel chelate affinity chromatography (Chelating Sepharose FF;
Amersham Pharmacia Biotech) using a pH gradient. NY-ESO-1
and SSX proteins were eluted in 8 M urea, 100 mM phosphate,
10 mM Tris, pH 4.5. The purified proteins were reactive with
anti–ESO-1 and anti-SSX mAbs by Western blot analysis, and
purity was 
 
.
 
80% by SDS-PAGE.
 
Preparation of Tumor Cell Lysate.
 
1.5 
 
  
 
10
 
6
 
 NW-MEL-38 tu-
mor cells were lysed in 50 
 
m
 
l H
 
2
 
O by several cycles of rapid
freeze–thawing in liquid nitrogen.
 
Generation of Monocyte-derived Autologous APCs.
 
PBMCs, de-
pleted of CD4
 
1
 
 and CD8
 
1
 
 T lymphocytes using magnetic beads
(Minimacs; Miltenyi Biotec), were seeded in 24-well plates at 4 
 
 
 
10
 
6
 
 cells/well, and allowed to adhere to plastic for 24 h. Nonad-
herent cells were removed, and remaining cells were used as
APCs and cultured with 1,000 U/ml GM-CSF (Leukomax; San-
doz) and 1,000 U/ml IL-4 (Pharma Biotechnologie Hannover)
for 5 d in X-vivo 15 medium (BioWhittaker) at 2 ml/well.
 
Table I.
 
Patient Disease NY-ESO-1 mRNA NY-ESO-1 antibody HLA-A alleles HLA-DR alleles
MZ19 Melanoma
 
1 1
 
A2 DRB1
 
*
 
0101
NW14 Melanoma
 
1 1
 
A2 DRB1
 
*
 
0101, 0102, 0104
DRB1
 
*
 
0801, 0803, 0806, 0810
NW29 Melanoma Unknown
 
1
 
A2 DRB1
 
*
 
1501–1505; 1601–1603; 1605
DRB1
 
*
 
0701
DRB4
 
*
 
0101–0103
DRB5
 
*
 
0101
NW37 Melanoma
 
1 1
 
A2 DRB1
 
*
 
1401; 1407–1408; 0901
DRB3
 
*
 
0201–0203
DRB4
 
*
 
0101–0103
NW408 Melanoma
 
1 1
 
A2 DRB1
 
*
 
0101, 0102, 0104
DRB3
 
*
 
0201–0202, 0301
DRB
 
*
 
1101, 1104, 1106, 1108–1113
NW690 Sarcoma
 
1 1
 
A2 DRB1
 
*
 
1501–1505; 1601–1603; 1605
DRB1
 
*
 
0801; 0803; 0806; 0810
DRB5
 
*
 
0101
NW731 Melanoma
 
1 1
 
A2 DRB1
 
*
 
0101
DRB1
 
*
 
1501–1505
NW38 Melanoma
 
1 1
 
A2 DRB1
 
*
 
0101; 0701
DRB4
 
*
 
0101–0103
NW-MEL-38 Melanoma
 
1
 
NA A2 DRB1
 
*
 
0101; 0701
(cell line) DRB4
 
*
 
0101–0103
NY-ESO-1 mRNA expression in tumor tissues, status of NY-ESO-1–specific serum antibody, and HLA typing of eight tumor patients and melanoma
cell line NW-MEL-38. NA, not applicable.
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For the assessment of HLA class II–restricted presentation of
NY-ESO-1 epitopes after incubation of APCs with a lysate of
the NY-ESO-1–expressing melanoma cell line NW-MEL-38,
APCs were treated on day 6 of in vitro culture with 1,000 U/ml
IL-4, 1,000 U/ml IL-6, 10 ng/ml IL-1
 
b
 
, 10 ng/ml TNF-
 
a
 
 (IL-4,
IL-6, IL-1
 
b
 
, and TNF-
 
a
 
 obtained from Pharma Biotechnologie
Hannover), 1,000 U/ml GM-CSF, and 1 
 
m
 
g/ml prostaglandin
(Sigma Chemical Co.). On day 7, 20 
 
m
 
l of NW-MEL-38 tumor
cell lysate was added to the APCs and cocultured for 40 h. APCs
were then washed twice and used in ELISPOT assays at 3 
 
  
 
10
 
4
 
cells/well.
 
Preparation of CD4
 
1
 
 T Lymphocytes.
 
CD4
 
1
 
 T lymphocytes were
separated from PBMCs using magnetic beads (Minimacs; Mil-
tenyi Biotec) according to the manufacturer’s instructions and
frozen until use. T cell fractions were confirmed to contain 98%
CD4
 
1
 
 T lymphocytes by FACS
 
®
 
 analysis.
 
Generation of Peptide-specific CD4
 
1
 
 T Cell Lines.
 
10
 
6 
 
autologous
irradiated APCs pulsed with DRB4
 
*
 
0101-0103–binding NY-
ESO-1 peptides at 10 
 
m
 
g/ml were seeded in 24-well plates, and
CD4
 
1
 
 T lymphocytes were added at 2.5 
 
  
 
10
 
5
 
 cells/well. Cul-
ture medium consisted of RPMI 1640 medium supplemented
with 10% human serum, 
 
l
 
-asparagine (50 mg/l), 
 
l
 
-arginine (242
mg/l), 
 
l-glutamine (300 mg/l), IL-2 (2.5 ng/ml), and IL-4 (5
U/ml). CD41 T cells were restimulated weekly with autologous
APCs pulsed with the same peptides.
ELISPOT Assay. APCs were harvested and pooled on day 5,
and reseeded in 96-well flat-bottomed nitrocellulose plates
(MAHAS4510; Millipore) at 3.5   104 cells/well. Before the ad-
dition of cells, plates had been coated overnight at 48C with 5 mg/
ml anti–IFN-g antibody (Hoelzel Diagnostik). APCs were pulsed
with NY-ESO-1 peptides at 4 mg/well, or recombinant NY-
ESO-1 or SSX protein at 2 mg/well for control. APCs pulsed
with NW-MEL-38 tumor cell lysate were used at 3   104 cells/
well. Freshly isolated CD41 T lymphocytes (105 cells/well) or
peptide-specific CD41 T cell lines (104 cells/well) were added in
RPMI 1640 medium, supplemented with 10% human serum,
l-asparagine (50 mg/l), l-arginine (242 mg/l), l-glutamine (300
mg/l) in a final volume of 100 ml. After incubation for 48 h (16 h
for testing the tumor cell lysate) at 378C in a water-saturated at-
mosphere, the plates were washed extensively (six times with a
solution of 0.05% Tween 20/PBS) and supplemented with the
biotinylated anti–IFN-g detection antibody (Hoelzel Diagnostik)
at 0.5 mg/ml. After incubation for 2 h at 378C, plates were
washed and developed with ABC-AP Vectastain (Vector Labs)
for 1 h. After addition of substrate (BCIP/NPT) and 10 min of
incubation, plates were prepared for microscopic counting of the
blue spots. The number of blue spots per well was determined as
the frequency of CD41 T lymphocytes specifically recognizing
NY-ESO-1–derived, HLA class II–restricted peptides, or the
processed recombinant NY-ESO-1 or SSX protein. Controls
were the reagents alone, effector cells alone (spontaneous IFN-g
release), and APCs alone. The difference between the numbers
counted in peptide- or protein-stimulated versus nonstimulated
wells was calculated as the effective number of peptide-specific T
lymphocytes above background. In HLA class II blocking experi-
ments, DR-specific antibody L243 was added at 2 mg/well be-
fore incubation of APCs with peptides, and antibody W6/32 was
used at 2 mg/well as a control.
Proliferation Assay. Autologous or allogeneic HLA-DRB4*0101–
0103-matched irradiated APCs derived from melanoma patients
NW29 and NW37 pulsed with peptides were plated in 96-well
round-bottomed plates at 105 cells/well in RPMI 1640 medium
supplemented with 10% human serum, l-asparagine (50 mg/l),
l-arginine (242 mg/l), l-glutamine (300 mg/l), IL-2 (2.5 ng/ml),
and IL-4 (5 U/ml), and CD41 selected T lymphocytes were
added at 5   104 cells/well. On day 13, after one restimulation
with peptide-pulsed APCs on day 7, cultures were incubated
with [3H]TdR (Amersham Pharmacia Biotech) at 0.5 mCi/well
for 16 h. Cells were then collected, and thymidine incorporation
was measured in a liquid scintillation counter.
Results
NY-ESO-1–specific CD41 T Cell Responses. CD41 T cell
responses against autologous APCs pulsed with the recom-
binant NY-ESO-1 protein were observed in all patients
with NY-ESO-1–expressing tumors. 28 overlapping 18-mer
NY-ESO-1 peptides were tested for recognition by CD41
T lymphocytes in the same assays. Two patients, NW29
and NW37, showed a similar pattern of recognition: with
three NY-ESO-1–derived peptides (peptide 21, PLPVPGV-
LLKEFTVSGNI, p115–132; peptide 22, VLLKEFTVSGNI-
LTIRLT, p121–138; peptide 25, AADHRQLQLSISSCL-
QQL, p139–156), significant numbers of IFN-g spots were
induced in at least three independent experiments (Fig. 1).
Induction of peptide-specific IFN-g spots was efficiently
Figure 1. ELISPOT assays showing
CD41 T cell recognition of APCs
pulsed with NY-ESO-1. Numbers of
IFN-g spots/100,000 CD41 selected
T lymphocytes are shown. CD41 T
cells were tested against autologous
APCs, either alone or after pulsing
with NY-ESO-1–derived peptides or
recombinant NY-ESO-1 protein.
Peptides tested were different NY-
ESO-1–derived 18-mer peptides. Pa-
tients NW29 and NW37, who share
the HLA-DRB4*0101–0103 alleles,
show the same pattern of peptide rec-
ognition, whereas the HLA-DRB4*
0101–01032 patient NW690 shows
recognition of NY-ESO-1 protein
only, suggesting that peptides 21, 22,
and 25 are presented by HLA-DRB4*
0101–0103.
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blocked with anti-DR antibody L243, suggesting that pep-
tide recognition was DR-restricted (Fig. 2), whereas anti-
body W6/32 had no detectable blocking effect. ELISPOT
results were confirmed in proliferation assays, which show
specific proliferation against the same peptides (representa-
tive results are presented in Fig. 3). Since only two of seven
patients displayed the same pattern of peptide recognition,
it is suggested that the peptides recognized are presented by
HLA class II alleles shared by both patients, which are
DRB4*0101–0103 (Table I). Results presented here have
been confirmed in at least two independent experiments.
Peptide-specific CD41 T Cell Lines. Of patients NW29
and NW37, peptide-specific CD41 T cell lines were gen-
erated by repetitive stimulation with peptides 22 and 25.
Fig. 4 shows the specific recognition of the stimulating
peptide, the recombinant NY-ESO-1 protein, but not of
the recombinant SSX protein used as a control.
Recognition of Naturally Processed NY-ESO-1 Epitopes by
the Peptide-specific NW29 CD4/25 and NW37 CD4/22 T
Cell Lines. The CD41 T cell lines NW29 CD4/25 and
NW37 CD4/22 were generated by repetitive stimulation
with the DRB4*0101–0103-restricted synthetic NY-ESO-
1–derived peptides 25 and 22. To show that these CD41 T
cell lines also recognize naturally processed NY-ESO-1
epitopes in the context of HLA-DRB4*0101–0103, ELI-
SPOT assays were performed with autologous APCs pulsed
with a lysate of the NY-ESO-1–expressing tumor cell line,
NW-MEL-38. The significant recognition of NW-MEL-
38–pulsed APCs by both CD41 T cell lines suggests that
the NY-ESO-1–derived peptides 22 and 25 represent nat-
urally processed epitopes (Fig. 5). 
Discussion
The CT antigen NY-ESO-1 appears to be highly im-
munogenic and is therefore regarded as a promising target
for immunotherapeutic interventions in patients with NY-
ESO-11 cancers. NY-ESO-1 is expressed in different types
of malignant tumors, e.g., melanoma, and breast, lung,
head and neck, gastrointestinal tract, bladder, and prostate
cancer (1). In contrast to other CTL-defined TAs, sponta-
neous humoral and cellular NY-ESO-1–specific immune
responses can be observed in z 50% of patients with ad-
vanced NY-ESO-11 tumors (2, 3), suggesting efficient ac-
tivation of specific CD41 and CD81 T lymphocytes during
cancer development. Much attention has been paid to
CD81 CTLs, regarded as the effectors that directly mediate
lysis of tumor cells upon specific interaction with peptide–
HLA class I complexes expressed on the tumor cell surface.
Early clinical trials with HLA class I–restricted peptides de-
rived from different TAs have shown tumor regressions in
single patients, which could be correlated in some of the
studies with a measurable increase of peptide-specific CTL
reactivity in vivo (4–6). We recently succeeded in identify-
ing HLA class I–restricted NY-ESO-1 peptide epitopes
recognized by CTLs of cancer patients (3). These HLA
class I–binding NY-ESO-1 epitopes are now used in clini-
cal trials to evaluate their efficacy in the induction of pep-
tide-specific CTL responses in vivo. However, active im-
munization may become more efficient if antigen-specific
Figure 2. ELISPOT assays showing the blocking effect of HLA-DR–
specific antibody L243 on CD41 T cell recognition of NW29 APCs
pulsed with the DRB4*0101–0103-binding NY-ESO-1 peptide 25. Ex-
periments were performed as in the legend to Fig. 1, with L243 added at
2 mg/well to one set of experiments. HLA class I–binding antibody W6/32
was used at 2 mg/well as a control. Results showed a decrease of positive
spots by .50% in the presence of L243 (gray bars), whereas W6/32
(white bars) did not affect the specific recognition of peptide 25.
Figure 3. Standard [3H]TdR proliferation assay showing specific prolif-
erative response of peptide-stimulated NW29 CD41 T cells to autol-
ogous APCs alone or pulsed with the respective DRB4*0101–0103-
restricted NY-ESO-1 peptides (21, 22, and 25).
Figure 4. ELISPOT assay with autologous APCs pulsed with NY-
ESO-1–derived peptide 22, and the recombinant NY-ESO-1 and SSX
proteins. The CD41 T cell line NW37 CD4/22 was used as effectors.
Bars indicate the number of spots/104 NW37 CD4/22 cells. Values rep-
resent the results of three independent experiments.
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CD41 T cell responses are stimulated simultaneously by an-
tigen-specific HLA class II peptides, as suggested by several
murine tumor models (7). Further, the role of CD41 T cells
in antitumor immunity can be explored in more detail using
antigen-specific HLA class II peptide epitopes for monitor-
ing antigen-specific immune responses in cancer patients.
We describe here the identification of HLA class II–
restricted NY-ESO-1 peptides using the ELISPOT tech-
nique, a method that is sensitive enough to reflect the status
of antigen-specific T cell immunity without prestimulation
of effector cells in vitro for extended periods of time (8).
To evaluate antigen-specific CD41 T cell responses, we
employed APCs derived from PBMCs, which are capable
of efficiently processing extracellular proteins into the en-
dogenous HLA class II presentation pathway. Our results
show that CD41 T cell responses against NY-ESO-1 pro-
tein processed by autologous APCs were observed in all
seven patients examined. Of a panel of 18-mer NY-ESO-1
peptides, three were recognized by CD41 T cells of two
patients who shared the HLA-DRB4*0101–0103 alleles.
Peptide-specific CD41 T cell reactivity assessed in
ELISPOT experiments was confirmed by standard prolifer-
ation assays. To further confirm the specificity of recogni-
tion, we established CD41 T cell lines from two patients
sharing the HLA-DRB4*0101–0103 alleles by repetitive
stimulation with NY-ESO-1–derived peptides (peptides 22
and 25). These peptide-specific CD41 T cell lines showed
specific recognition of the stimulating peptides and the re-
combinant NY-ESO-1 protein, but not of the recombi-
nant control protein SSX. The peptide-specific CD41 T
cell lines were further used to confirm the specificity
against naturally processed NY-ESO-1–derived epitopes. A
lysate of the NY-ESO-1–expressing melanoma cell line
NW-MEL-38 was loaded onto autologous APCs, and spe-
cific recognition by both CD41 T cell lines was shown.
This observation suggests (a) that the NY-ESO-1–derived
peptides identified here represent the naturally processed
NY-ESO-1 epitopes, and (b) that the PBMC-derived APCs
used in the ELISPOT experiments efficiently process and
present antigenic peptides in the context of HLA class II.
Specific CD41 T cell responses against different human
tumor antigens have been described (9–11), some of which
directly mediate lysis of tumor cells (12). However, the
major role of CD41 T cell immunity is believed to be in
the regulation and coordination of different immune effec-
tor functions (13, 14). Although the lytic capacity of adop-
tively transferred CD81 CTLs is not further improved by
coadministration of CD41 T cells (15, 16), it is well docu-
mented that the priming of a CTL response is significantly
enhanced by CD41 T cells specific for the same antigen
(17). The helper effect of CD41 T cells is dependent on
the CD40 receptor–ligand interaction between APCs and
antigen-specific CD41 T cells (18, 19). Signaling through
CD40 ligation results in the release of proinflammatory cy-
tokines, upregulation of adhesion and costimulatory mole-
cules, and the production of IL-12 (20, 21). Therefore, im-
munization with peptides derived from TAs may lead to
improved immune responses if HLA class II–binding
epitopes stimulating CD41 T cells are injected simulta-
neously with HLA class I–restricted epitopes derived from
the same antigen.
The central role of CD41 T cells for the induction and
regulation of antigen-specific CTL responses is well estab-
lished. Less is known about the significance of CD41 T
cells for the initiation of specific antibody responses. Since
NY-ESO-1 elicits both cellular and humoral immune re-
sponses that can be detected simultaneously in cancer pa-
tients, it may be assumed that the function of CD41 T cells
is modulated towards a Th1 or Th2 type of immune re-
sponse by different cytokine profiles in the tumor environ-
ment (22). In addition, the frequency and activity of mac-
rophages, dendritic cells, and B lymphocytes functioning as
potential APCs in tumor tissues may affect the type of Th
response (23). We have found that the development of
NY-ESO-1 antibody titers correlates with the clinical per-
sistence of NY-ESO-1–expressing tumors (24). With the
definition of HLA class II–binding peptides in NY-ESO-1,
it is now feasible to investigate the specific role of CD41 T
cells induced by HLA class II–binding peptides, and its cor-
relation to cellular and/or humoral immune responses to
NY-ESO-1–expressing tumors in cancer patients.
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Figure 5. ELISPOT assay with au-
tologous APCs derived from patients
NW29 and NW37 pulsed with NW-
MEL-38 lysate and tested for specific
recognition with the CD41 T cell
lines NW29 CD4/25 and NW37
CD4/22. Bars indicate the number of
spots/104 NW37 CD4/22 cells.
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